Navigation Links
Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Date:9/22/2008

n or more than 60 years of age). The prognostic value of various molecular markers will also be studied.

The trial is expected to start this fall and will be conducted at various sites in France.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Laromustine (Cloretazine(R) (VNP40101M)), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia (AML). The Company is also conducting clinical trials of laromustine (Cloretazine(R) (VNP40101M)) with cytarabine in elderly patients with AML, with temozolomide in patients with brain tumors, and with stem cell transplants in patients with advanced hematologic malignancies. A Phase III trial of laromustine (Cloretazine(R) (VNP40101M)) in combination with standard induction therapy in previously untreated AML and high-risk myelodysplastic syndrome (MDS) patients is expected to start this fall. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's web site at http://www.vionpharm.com.

About Institut Paoli-Calmettes

The Institut Paoli-Calmettes Cancer Center (IPC) is a private non-profit institution. Located in Marseille, IPC is a regional university hospital that is part of a network of 20 cancer treatment centers in France. Institut Paoli-Calmettes sets out to organize and prioritize the synergies between fundamental research, transfer laboratories, biotechnology companies and hospital departments. Employing the latest in innovation, Institut Paol
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... 17 Instacare Corp. (OTC Bulletin Board: ... life-enhancing prescription drugs and diagnostics and at home ... leading developer and provider of e-health technologies and ... today that as part of the preparation of ... to add two new Directors and has rejected, ...
(Date:12/17/2009)... -- Express Scripts, Inc. (Nasdaq: ESRX ... management companies in North America, announced today ... association of seizure risk among epilepsy patients ... The study found no evidence that switching ... generic substitution, was associated with increased emergency ...
(Date:12/17/2009)... BioTherapeutics, Inc. (NYSE-Amex: PLX ) today announced ... Sales and Commercial Affairs. In this newly ... responsible for all commercial activities, including pre-launch and ... the collaboration agreement between the Company and Pfizer ... emerge from the Company,s pipeline. Ms. Lauterbach ...
Breaking Medicine Technology:Instacare Corp. Board of Directors Sets Growth Plans for 2010 2Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity 2Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 2Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 4Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 1Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 2Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 3Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 1Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 2Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 1Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 2
... Abeome Corporation, a,Georgia-based biotech company, announced today ... a collaboration with Cato Research Ltd.,its global ... collaboration will help support continued development of ... technology vastly improves the development of,monoclonal antibodies ...
... as the Clinical Gold Standard ... from Decision Resources, WALTHAM, Mass., July 15 ... and advisory firms focusing on pharmaceutical and,healthcare issues, ... of depressive mood episodes in patients who suffer ...
Other Medicine Technology:Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic 2Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder 2
(Date:12/17/2009)... Dec. 17 The Department of Justice ... state of New York have entered into settlement ... allegations that they submitted false claims to the ... The New York Medicaid program provides coverage for ... valid certificates showing that they received proper training. ...
(Date:12/17/2009)... Life" in Majority Leader,s Revisions to Senate Health ... 17 Americans United for Life Action ... to Senate Majority Leader Harry Reid as he ... revisions to a bill - to the Senate ... to include "specific language that ensures your legislation ...
(Date:12/17/2009)... ,Hopenhagen, the city is calling itself, ... international conference on climate change. Narconon has its ... of the worldwide Narconon drug education ... from climate change. But the streets thrum with ... by with flashing blue lights - a youth ...
(Date:12/17/2009)... not be beneficial , , THURSDAY, Dec. 17 (HealthDay News) ... the immediate effect of the fish oil fatty acids ... increase in blood fats and the molecules that help ... that the acute response has some potentially negative effects ... long-term intake," said Lindsay E. Robinson, an associate professor ...
(Date:12/17/2009)... fall down on prevention, experts say , , THURSDAY, ... surgeons are getting better at treating heart attacks ... ignoring the basic rules for preventing them, according ... , Topping the list: too little exercise, too ... adults surveyed last year reported no activity vigorous ...
Breaking Medicine News(10 mins):Health News:Three New York City Home Health Agencies Pay $9.7 Million to the United States to Settle False Claims Act Claims 2Health News:Pro-Life Leader Sends Urgent Letter to Senator Reid 2Health News:Save the Planet. Stop Smoking Dope, Says Narconon 2Health News:Could Omega-3s Boost Blood Fat Levels? 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 3
... support program with the goal to help healthcare professionals optimize outcomes ... ... (PRWEB) January 29, 2009 -- Though rare, gastrointestinal stromal tumors (GISTs) ... with an estimated 3,300 to 6,000 new cases reported each year ...
... message during the big gameMINNEAPOLIS, Jan. 29 The ... ads as it is for the actual football game. ... from ClearWay Minnesota that somberly reminds Minnesotans that "we ... and health consequences of tobacco use are explored though ...
... Researchers from Boston University School of Medicine (BUSM) and ... have found that children born more than three months premature, ... the modified checklist for autism in toddlers (M-CHAT). Children ... for developing autism. These findings appear in the January ...
... A new way of making LEDs could see household ... years. , Gallium Nitride (GaN), a man-made semiconductor ... light but uses very little electricity. Until now high ... wide spread use in homes and offices. , ...
... years; lawmakers demand criminal probe after U.S. health officials ... 2007 and 2008. , , WEDNESDAY, Jan. 28 (HealthDay News) ... late Wednesday for all peanut products made over the ... the current salmonella outbreak. , The recall was initiated ...
... Jan. 28 Consumer Watchdog warned that the move by ... California will lead to degradation of the quality of patient ... the interest of nursing home owners over patients.The current agreements ... protect the right of caregivers to blow the whistle on ...
Other Medicine News:Health News:Novartis Oncology Launches GIST Alliance™ for Healthcare Professionals Treating Gastrointestinal Stromal Tumors 2Health News:Novartis Oncology Launches GIST Alliance™ for Healthcare Professionals Treating Gastrointestinal Stromal Tumors 3Health News:New Super Bowl Ad Reminds Minnesotans: 'We All Pay the Price for Tobacco' 2Health News:New Super Bowl Ad Reminds Minnesotans: 'We All Pay the Price for Tobacco' 3Health News:Study finds preemies more likely to score positive 2Health News:Low-cost LEDs to slash household electric bills 2Health News:All Products at Georgia Peanut Plant Recalled 2Health News:All Products at Georgia Peanut Plant Recalled 3Health News:All Products at Georgia Peanut Plant Recalled 4
Inquire...
... Array Multifocal IOL was designed to provide ... from glasses in most situations. While distance ... similar to that of a single vision ... better and about 19 in 20 people ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... The Zeus Scientific, Inc. ... for the qualitative and quantitative ... human serum by the indirect ... assay can determine or confirm ...
Medicine Products: